Latest News about NVS
Recent news which mentions NVS
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
From Benzinga
This Drug By Roche And Novartis Reduces Allergic Reactions Across Multiple Foods For People With Food Allergies
February 26, 2024
From Benzinga
Move Over Magnificent 7, Say Hello to the GRANOLAS
February 22, 2024
From InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
February 21, 2024
From InvestorPlace
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
From InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
From InvestorPlace
From Benzinga
JP Morgan's Bullish View On This Chinese Biotech, Says Pullback Creates Entry Point
February 06, 2024
From Benzinga
From Benzinga
Why Is MorphoSys (MOR) Stock Up 50% Today?
February 05, 2024
From InvestorPlace
From Benzinga
3 Fabulous Dividend Stocks to Buy in February
February 04, 2024
From Motley Fool
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
February 02, 2024
From Benzinga
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 31, 2024
From Benzinga
Why Is European Pharma Giant Novartis Stock Trading Lower Today?
January 31, 2024
From Benzinga
Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's Presser
January 31, 2024
From Benzinga
Alphabet Reports Q4 Results, Joins AMD, Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 31, 2024
From Benzinga
Earnings Scheduled For January 31, 2024
January 31, 2024
From Benzinga
3 Hidden Healthcare Stocks Poised for a Breakout This Year
January 30, 2024
From InvestorPlace
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
January 29, 2024
From Benzinga
Gilead's Tecartus Dropped From FDA List Of CAR-T Therapy With Updated Label Warning Of "Risks Of Secondary Cancer'
January 24, 2024
From Benzinga
From Benzinga
Cytokinetics' Heart Drug Is A Multi-Billion Dollar Opportunity By 2032 Despite Novartis Setback: Analyst
January 12, 2024
From Benzinga
Novartis Retreats From Cytokinetics Deal, Dashing Hopes For Multi-Billion Dollar Acquisition
January 11, 2024
From Benzinga
What's Been Happening With Cytokinetics Stock?
January 09, 2024
From Benzinga
From Benzinga
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
January 08, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.